Miltenyi Biotec, Gmbh

Miltenyi Biotec B.v. Co., Kg

Iris Bürger

Andrzej Dzionek

Volker Nolle

Martin Meyer

Stefan Tomiuk

Nicole Susann Eckardt

Anne Levin

The present invention relates to polypeptides comprising a mutant human IgG, which mutant human IgGis capable of increasing the binding to and activation of immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing Fc&#x3b3;RIIb/c (CD32b), but not Fc&#x3b3;RIIa (CD32a). More specifically, the invention relates to polypeptides comprising at least one human IgGwith a lysine at position 409 (409K), using the EU index according to Kabat et al., which IgGis capable of binding to human CD32b/c with a statistically significant (p=0.05) higher binding affinity than a wild-type human IgGand than a wild-type human IgG, for use in the prevention and/or treatment of an autoimmune disease or allergy, as further defined in the claims.

Methods of activating CD32b/c comprising administering an antibody that binds BDCA-2 (CD303)

The present invention provides a humanized antibody or fragment thereof specific for the antigen CD45R0, wherein said antibody or fragment thereof comprises a humanized heavy chain variable domain comprising a CDR1 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2, and a CDR3 region of SEQ ID NO:3, and a humanized light chain variable domain comprising a CDR1 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5, and a CDR3 region of SEQ ID NO:6. It is also provided the use of the present antibody or fragment thereof for enrichment or depletion of CD45R0-expressing cells from a sample comprising CD45R0-expressing cells.

Humanized antibody or fragment thereof specific for CD45R0

Growing community of inventors

Rösrath, Germany

Iris Bürger